Biotech company Bioptimus achieves a $76 million funding milestone and gears up to introduce a groundbreaking foundation model in the field of biology.
Bioptimus, a pioneering company, has announced a significant funding milestone of $76M, with the latest injection of $41M led by Cathay Innovation. This investment will accelerate Bioptimus's mission to build the world's first universal AI foundation model for biology.
Bioptimus is redefining how biological research is approached by addressing the siloed nature of biological understanding. The company's revolutionary approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology. This unique perspective promises to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
The new model developed by Bioptimus, H-Optimus-0, has outperformed all other pathology models in independent benchmarks. It has an unparalleled ability to predict gene expression from morphology and to subtype ovarian cancer with exceptional accuracy. This groundbreaking model was assessed by Harvard Medical School's HEST program and the University of Leeds.
Bioptimus leverages a team of world-class experts, state-of-the-art AI technologies, and unique proprietary data at scale. The funding will not only support the development of H-Optimus-0 but also create biological innovation for medical, biotech, cosmetic industries, and beyond.
The funding round was also participated by Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf. Cathay Innovation, a multistage venture capital firm, led the latest funding round. Known for connecting startups with investors and its ecosystem of leading Fortune500 corporations, Cathay Innovation aims to help Bioptimus scale.
A new model for data processing in neural networks has been developed, as mentioned on Arxiv.org at https://arxiv.org/abs/2405.09990. The Mahmood Lab has also developed a model called HEST for Hierarchical Embedding of Spatial Transcriptomics, available at https://github.com/mahmoodlab/HEST.
With this funding, Bioptimus is poised to revolutionise the field of biology and pave the way for unprecedented scale and dimension in the simulation of biology. The company's new model will allow for a simulation of biology that was previously unimaginable, marking a significant step forward in the world of AI and biology.
